Abstract Treatment of patients with hepatocellular carcinoma (HCC) remains a serious
challenge due to high heterogeneity and limited treatment options. In the past few decades …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths in the
world, and for patients with advanced disease there are few therapeutic options available …

The application of immune checkpoint inhibitors (ICIs) has markedly enhanced the treatment
of hepatocellular carcinoma (HCC), and HCC patients who respond to ICIs have shown …

Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its
incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of …

In advanced-stage hepatocellular carcinoma (HCC), systemic treatment represents the
standard therapy. Target therapy has marked a new era based on a greater knowledge of …

The treatment of hepatocellular carcinoma (HCC), particularly advanced HCC, has been a
serious challenge. Immune checkpoint inhibitors (ICIs) are landmark drugs in the field of …

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related
deaths in the world. More than half of patients with HCC present with advanced stage, and …

Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world
and its incidence is increasing in many countries. In recent years, with the deepening …

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in humans,
which is prone to recurrence and metastasis and has a poor prognosis. The occurrence and …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy worldwide
and a leading cause of death worldwide. Its incidence continues to increase in the US due to …